Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 20Unknown 5Recruiting 2Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1Breast 1

Conditions

Breast Neoplasms 848Carcinoma, Non-Small-Cell Lung 549Neoplasms 510Prostatic Neoplasms 501Lung Neoplasms 312Colorectal Neoplasms 307Multiple Myeloma 292Neoplasm Metastasis 250Melanoma 241Ovarian Neoplasms 215Leukemia, Myeloid, Acute 208Pancreatic Neoplasms 207Squamous Cell Carcinoma of Head and Neck 173Carcinoma, Renal Cell 165Recurrence 162Stomach Neoplasms 161Carcinoma, Hepatocellular 160Lymphoma 156Brain Neoplasms 152Glioblastoma 147Uterine Cervical Neoplasms 144Lymphoma, Non-Hodgkin 141Head and Neck Neoplasms 140Triple Negative Breast Neoplasms 136Leukemia, Lymphocytic, Chronic, B-Cell 136Urinary Bladder Neoplasms 135Precursor Cell Lymphoblastic Leukemia-Lymphoma 132Colonic Neoplasms 115Hematologic Neoplasms 113Lymphoma, Follicular 112

Interventions

olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Fanconi Anemia, Complementation Group D1 × Clear all
NCT03344965 2026-01-05

Olaparib In Metastatic Breast Cancer

Beth Israel Deaconess Medical Center

Phase 2 Active not recruiting
114 enrolled
BreastClassical hematology

Fanconi Anemia, Complementation Group D1, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡